Submissions for variant NM_002618.4(PEX13):c.661C>G (p.Leu221Val)

gnomAD frequency: 0.00005  dbSNP: rs192034592

Total submissions: 2

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV001041897	SCV001205548	uncertain significance	Peroxisome biogenesis disorder 11A (Zellweger)	2024-01-22	criteria provided, single submitter	clinical testing	This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 221 of the PEX13 protein (p.Leu221Val). This variant is present in population databases (rs192034592, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PEX13-related conditions. ClinVar contains an entry for this variant (Variation ID: 840010). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PEX13 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
PreventionGenetics, part of Exact Sciences	RCV004740548	SCV005361854	uncertain significance	PEX13-related disorder	2024-04-16	no assertion criteria provided	clinical testing	The PEX13 c.661C>G variant is predicted to result in the amino acid substitution p.Leu221Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.016% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.